Menu Search
Equities

Humacyte Inc

HUMA:NSQ

Humacyte Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.34
  • Today's Change-0.02 / -0.37%
  • Shares traded1.91m
  • 1 Year change+137.33%
  • Beta1.4598
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Humacyte Inc's revenues fell -100.00% from 1.57m to 0.00. has fallen 825.83% from a loss of 11.97m to a larger loss of 110.78m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-115.74%
Return on equity--
Return on investment-134.05%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Humacyte Inc fell by 68.97m. Cash Flow from Financing totalled 4.51m or -- of revenues. In addition the company used 73.31m for operations while cash used for investing totalled 173.00k.
Cash flow per share-1.29
Price/Cash flow per share--
Book value per share-0.5317
Tangible book value per share-0.5317
More ▼

Balance sheet in USDView more

Humacyte Inc uses little or no debt in its capital structure.
Current ratio1.10
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.